Report from the Western Canadian Gastrointestinal Consensus Cancer Conference—Management of Total Neoadjuvant Therapy in Rectal Cancer
Authors:
- Howard LimHoward Lim
- Aswin George AbrahamAAAswin George Abraham
- Shahid AhmedShahid Ahmed
- Shahida AhmedSAShahida Ahmed
- Carl J. BrownCBCarl J. Brown
- Bryan BrunetBBBryan Brunet
- Janine DaviesJDJanine Davies
- Corinne DollCDCorinne Doll
- Dorie-Anna DueckDDDorie-Anna Dueck
- Vallerie GordonVGVallerie Gordon
- Kimberly HagelKHKimberly Hagel
- Pamela HebbardPHPamela Hebbard
Open Access
- 8 February 2022
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 29 (2) , 924-927
Abstract
An educational session related to the Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held virtually on 14 October 2020. The WCGCCC is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba), who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists, radiologists, and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of total neoadjuvant therapy in rectal cancer.Keywords
This publication has 4 references indexed in Scilit:
- Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial.Journal of Clinical Oncology, 2021
- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trialThe Lancet, 2017